Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early Detection of Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease by Measuring Serum Adiponectin Level.
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 23, 2021
CompletedFirst Posted
Study publicly available on registry
November 3, 2021
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedNovember 3, 2021
October 1, 2021
1 year
October 23, 2021
October 23, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.
measure level of serum Adiponectin in non-alcoholic fatty liver patients to detect early renal impairment.
baseline
Study Arms (2)
cases
non-alcoholic fatty liver patients
control
healthy persons
Interventions
serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
Eligibility Criteria
cases are Non-alcoholic fatty liver patients who do not having any other health problem. control group is healthy individuals.
You may qualify if:
- Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .
- Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2.
- The Control group are completely healthy subjects without any systemic or liver and kidney affection
You may not qualify if:
- Patients less than 18 yrs \& more than 60 yrs .
- All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002 Sep;34(9):469-74. doi: 10.1055/s-2002-34785.
PMID: 12384822RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mohamed Hassan, Profissor.as
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Hend Abdelrheem
Study Record Dates
First Submitted
October 23, 2021
First Posted
November 3, 2021
Study Start
December 1, 2021
Primary Completion
December 1, 2022
Study Completion
January 1, 2023
Last Updated
November 3, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share